Published in Blood Weekly, April 22nd, 2004
Revenues for the fiscal third quarter were $27.9 million, up 10.7% from $25.2 million in the same period last year; $760,000 of this increase was due to price increases including group contract renewals at higher prices. Gross margin (gross profits as a percentage of sales) fell to 53.1%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.